BTIG Maintains Buy on MDxHealth, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro has maintained a Buy rating on MDxHealth (NASDAQ:MDXH) and increased the price target from $7 to $8.
March 07, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Mark Massaro has reaffirmed a Buy rating on MDxHealth and raised the price target from $7 to $8.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100